BACKGROUND/AIM: This observational study was conducted to evaluate the safety and efficacy of the conversion from calcineurin inhibitors (CNIs) to sirolimus (SRL)-based immunosuppressive therapy in kidney transplantation. MATERIALS AND METHODS: Sixty-four kidney recipients of mean age 38.3 +/- 14.6 years were converted to SRL. The main reasons for conversion were elective in 45 (70.3%) and biopsy-proven chronic allograft nephropathy in 11 (17.2%). The primary CNI used was cyclosporine A in 51 patients. Mean time to conversion was 50.5 months. After conversion, 61 patients received mycophenolate mofetil. We evaluated the impact of conversion on renal function for 5 years post-conversion. The overall mean follow-up time was 72.8 months. RESULTS: The analysis showed significant improvement in renal function at month 3 post-conversion (P < 0.05) with stabilization thereafter. Lipid parameters and blood sugar levels were similar pre- and post-conversion. Abnormal liver function test was transient in 12.8%. Reasons for SRL discontinuation were nephrotic range proteinuria in two patients and mouth ulceration in one. We compared patients with serum creatinine <140 micromol/l and those with serum creatinine > or = 140 micromol/l, and found that serum creatinine was an independent risk factor for chronic allograft dysfunction (P = 0.02). Graft loss occurred in three patients because of cardiovascular death in two and an acute rejection episode in one. CONCLUSIONS: We concluded that conversion from CNIs to SRL is an option and of benefit without significant acute rejection episodes or chronic allograft dysfunction especially in well-selected kidney transplant recipients with good graft function.
BACKGROUND/AIM: This observational study was conducted to evaluate the safety and efficacy of the conversion from calcineurin inhibitors (CNIs) to sirolimus (SRL)-based immunosuppressive therapy in kidney transplantation. MATERIALS AND METHODS: Sixty-four kidney recipients of mean age 38.3 +/- 14.6 years were converted to SRL. The main reasons for conversion were elective in 45 (70.3%) and biopsy-proven chronic allograft nephropathy in 11 (17.2%). The primary CNI used was cyclosporine A in 51 patients. Mean time to conversion was 50.5 months. After conversion, 61 patients received mycophenolate mofetil. We evaluated the impact of conversion on renal function for 5 years post-conversion. The overall mean follow-up time was 72.8 months. RESULTS: The analysis showed significant improvement in renal function at month 3 post-conversion (P < 0.05) with stabilization thereafter. Lipid parameters and blood sugar levels were similar pre- and post-conversion. Abnormal liver function test was transient in 12.8%. Reasons for SRL discontinuation were nephrotic range proteinuria in two patients and mouth ulceration in one. We compared patients with serum creatinine <140 micromol/l and those with serum creatinine > or = 140 micromol/l, and found that serum creatinine was an independent risk factor for chronic allograft dysfunction (P = 0.02). Graft loss occurred in three patients because of cardiovascular death in two and an acute rejection episode in one. CONCLUSIONS: We concluded that conversion from CNIs to SRL is an option and of benefit without significant acute rejection episodes or chronic allograft dysfunction especially in well-selected kidney transplant recipients with good graft function.
Authors: Manuel Pascual; Tom Theruvath; Tatsuo Kawai; Nina Tolkoff-Rubin; A Benedict Cosimi Journal: N Engl J Med Date: 2002-02-21 Impact factor: 91.245
Authors: V Ram Peddi; Stephen Jensik; Mark Pescovitz; John Pirsch; Scott H Adler; J Richard Thistlethwaite; Flavio Vincenti; David J Cohen Journal: Clin Transplant Date: 2005-02 Impact factor: 2.863
Authors: Christopher J E Watson; John Firth; Paul F Williams; John R Bradley; Nicholas Pritchard; Afzal Chaudhry; Jane C Smith; Christopher R Palmer; J Andrew Bradley Journal: Am J Transplant Date: 2005-10 Impact factor: 8.086
Authors: Giovanni Stallone; Barbara Infante; Antonio Schena; Michele Battaglia; Pasquale Ditonno; Antonia Loverre; Loreto Gesualdo; Francesco Paolo Schena; Giuseppe Grandaliano Journal: J Am Soc Nephrol Date: 2005-10-19 Impact factor: 10.121
Authors: I A MacPhee; J A Bradley; J D Briggs; B J Junor; S G MacPherson; M A McMillan; R S Rodger; M A Watson Journal: Transplantation Date: 1998-11-15 Impact factor: 4.939
Authors: Brian J Nankivell; Richard J Borrows; Caroline L-S Fung; Philip J O'Connell; Richard D M Allen; Jeremy R Chapman Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: Alfredo Mota; Manuel Arias; Eero I Taskinen; Timo Paavonen; Yves Brault; Christophe Legendre; Kerstin Claesson; Marco Castagneto; Josep M Campistol; Brian Hutchison; James T Burke; Sedar Yilmaz; Pekka Häyry; John F Neylan Journal: Am J Transplant Date: 2004-06 Impact factor: 8.086
Authors: Fritz Diekmann; Klemens Budde; Federico Oppenheimer; Lutz Fritsche; Hans H Neumayer; Josep M Campistol Journal: Am J Transplant Date: 2004-11 Impact factor: 8.086
Authors: R Brian Stevens; Kirk W Foster; Clifford D Miles; Andre C Kalil; Diana F Florescu; John P Sandoz; Theodore H Rigley; Tamer Malik; Lucile E Wrenshall Journal: PLoS One Date: 2015-10-14 Impact factor: 3.240